Samsung Bioepis Reports the Initiation of P-III Study for SB15 Proposed Biosimilar to Eylea (aflibercept)
Shots:
- The P-III study will compare the efficacy- safety- PK- and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration
- The company has two ophthalmology biosimilar candidates in clinical development- SB11 (ranibizumab) and SB15 (aflibercept). On May 18- 2020- Samsung Bioepis reports 24-week interim results from a P-III study of SB11 (proposed ranibizumab biosimilar)
- SB15 is a proposed biosimilar referencing Regeneron’s Eylea- currently under preclinical treatment for diabetic macular edema- diabetic retinopathy- retinal edema and retinal vein occlusion
Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Samsung Bioepis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
